DCTH Delcath Corp: Rasio rega marang prakiraan pendapatan
The forward P/S of Delcath Systems, Inc. (DCTH) reflects market expectations, where the 8.30 mark serves as the current benchmark. Delcath Systems, Inc. (DCTH) is advancing oncotherapy through clinical partnerships and the strategic acquisition of patents. Growth is driven by the implementation of the Hepzato system and the scaling of its medical center network. Laboratory operations do not harm the environment, strictly adhering to established environmental standards.
Rincian analitis perusahaan Delcath Corp (DCTH)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- rincian struktur utang lan likuiditas bisnis:
Rasio Total Utang marang Ekuitas Delcath Systems, Inc.|DCTH - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal Delcath Systems, Inc.|DCTH - Kewajiban utang agregat|Utang marang nilai buku Delcath Corp|DCTH - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Delcath Systems|Indikator likuiditas cepet delcath.com
- rincian asil keuangan lan kelipatan valuasi:
DCTH - Penghasilan resik perusahaan|Bathi sing dikarepake Delcath Systems, Inc.|DCTH - Periode bali modal bisnis|Prakiraan rega marang bathi Delcath|DCTH - Rasio nilai perusahaan marang wutah bathi|Pangali EV/EBITDA Delcath Corp|DCTH - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Delcath Systems|DCTH - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan delcath.com|DCTH - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Delcath Systems, Inc.
- data dodolan lan asil:
Ringkesan analisis perusahaan:Delcath Systems (DCTH)
The forward P/S ratio measures the current market value of Delcath Systems, Inc. (DCTH) relative to expected revenue, reflecting the degree of investor optimism priced in. By analyzing this forward price-to-sales multiple chart, one can assess the fairness of the valuation for Delcath Systems, Inc. (DCTH) during the organic rollout of its liver therapy system, a period where the absence of M&A activity makes future sales dynamics the sole driver of capitalization growth.
Pesaing wigati
Multiplikator Forward P/S ONC (BeiGene)|Halozyme Therapeutics, Inc. (HALO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RVMD - Rasio rega marang prakiraan pendapatan|AAPG: Rasio rega marang prakiraan pendapatan|CGON: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan urogen.com|BCAX (Bicara Therapeutics) - Multiplikator Forward P/S|Multiplikator Forward P/S Personalis Inc|Multiplikator forward rega marang pendapatan ERAS (Erasca Corp)|Rasio rega marang pendapatan sing dikarepake YMAB|Multiplikator Forward P/S AURA (Aura Biosciences, Inc.)|Rega forward marang dodolan CADL|ARAY: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SLS (SELLAS Life Sciences)|Actuate Therapeutics, Inc (ACTU) - Rasio rega marang prakiraan pendapatan|CTOR - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan HURA|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep protaratx.com TARA|Rasio rega marang prakiraan pendapatan Fate Therapeutics (FATE)|Rasio kapitalisasi marang dodolan sing dikarepake aadibio.com|TScan Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CSBR (Champions Oncology Inc)|XBiotech USA - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep CEL-SCI Corporation|OS Therapies (OSTX) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan radiopharmtheranostics.com|Rasio rega marang prakiraan pendapatan Artiva Biotherapeutics Inc.|Adlai Nortye Limited (ANL) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan VERU (Veru Inc.)|TPST (tempesttx.com) - Rega forward marang dodolan|Multiplikator Forward P/S XLO (Xilio Therapeutics)|Rasio kapitalisasi marang dodolan sing dikarepake Renovaro Biosciences (RENB)|MURA - Rasio rega marang prakiraan pendapatan|KAPA (Kairos Pharma Ltd) - Kapitalisasi marang prakiraan pendapatan|OKUR: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan CytoMed Therapeutics Limited|Multiplikator forward rega marang pendapatan CRIS|Apollomics Corp (APLM) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S THAR|advanbiomed.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S GNPX (Genprex, Inc.)|CLDI - Multiplikator forward rega marang pendapatan|SBFM: Multiplikator forward rega marang pendapatan|Xenetic Biosciences - Rasio rega marang pendapatan sing dikarepake|SLRX: Multiplikator Forward P/S|Kitov Pharma - Rega forward marang dodolan|AONC (American Oncology Network Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan beigene.com (BGNE)|Multiplikator Forward P/S CKPT|Multiplikator Forward P/S elevationoncology.com (ELEV)|Rasio rega marang prakiraan pendapatan iCAD ICAD|IKNA: Kapitalisasi marang prakiraan pendapatan|Notable Labs, Ltd. - Multiplikator Forward P/S|Viracta Therapeutics (VIRX) - Multiplikator forward rega marang pendapatan|MOR: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NAYA Biosciences Inc (NAYA)|Rasio rega marang prakiraan pendapatan Ascentage Pharma Group Ltd
